Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

FELIX was an open-label, multi-center, global ... In addition, 7% of patients experience grade ≥ 3 immune effector ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

The study of dielectric properties of biological materials, ranging from exosomes and cells to organoids and tissues, is a burgeoning field in biophysics and bioengineering. The primary challenge in ...

Like other CAR T-cell therapies, the drug's labeling has a boxed warning over risks of cytokine release syndrome (CRS), ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

With 140,000 neurons, 50 million synapses and over 100,000 cell label annotations, the fruit fly brain has been mapped and ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Learn about the benefits and risks of probiotic supplements and how to choose the best one for your health goals.

Should cellphones be banned in school? If so, what should those bans look like? We discuss it on this Talk of Alaska.